702 related articles for article (PubMed ID: 18316583)
1. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Han JY; Oh SH; Morgillo F; Myers JN; Kim E; Hong WK; Lee HY
J Natl Cancer Inst; 2005 Sep; 97(17):1272-86. PubMed ID: 16145048
[TBL] [Abstract][Full Text] [Related]
3. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
4. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
5. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
6. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
7. A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Oh SH; Kang JH; Kyu Woo J; Lee OH; Kim ES; Lee HY
Int J Cancer; 2012 Aug; 131(3):537-47. PubMed ID: 22113431
[TBL] [Abstract][Full Text] [Related]
8. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
Ren H; Tai SK; Khuri F; Chu Z; Mao L
Cancer Res; 2005 Jul; 65(13):5841-7. PubMed ID: 15994961
[TBL] [Abstract][Full Text] [Related]
11. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
12. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Kim YS; Jin HO; Seo SK; Woo SH; Choe TB; An S; Hong SI; Lee SJ; Lee KH; Park IC
Biochem Pharmacol; 2011 Aug; 82(3):216-26. PubMed ID: 21601561
[TBL] [Abstract][Full Text] [Related]
14. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
15. Regulation of survivin expression by IGF-1/mTOR signaling.
Vaira V; Lee CW; Goel HL; Bosari S; Languino LR; Altieri DC
Oncogene; 2007 Apr; 26(19):2678-84. PubMed ID: 17072337
[TBL] [Abstract][Full Text] [Related]
16. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
[TBL] [Abstract][Full Text] [Related]
17. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
[TBL] [Abstract][Full Text] [Related]
18. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
19. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]